Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general ...

Amid the rise of gut health and GLP-1 drugs in the UK, Potina is making high-fibre banana oat milks for improved children's ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Only 13 states currently offer Medicaid coverage for GLP-1 drugs, but the number of prescriptions and overall spending has ...

Hanmi Pharm. Co., Ltd. has announced promising research results for its novel obesity treatment, HM17321. This groundbreaking drug not only augments fat loss but also significantly increases lean ...

GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...

Full-Year Outlook Narrowed at Top and Bottom Ends "The sales growth is driven by increasing demand for our GLP-1-based ...